CSL Limited
CSL
株式のランク
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
株価
$138.33
時価総額
$66.38B
変化（1日）
-0.22%
変化（1年）
-3.31%
国
AU
取引 CSL Limited (CSL)
カテゴリー
Healthcare
CSL Limited（CSL）の収益
Jun 2026 時点の収益 TTM: $15.74B
CSL Limited の最新の財務報告によると、現在の収益 (TTM) は $15.74B です。2024 年には $14.69B の収益があり、これは 2023 年の $13.17B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
CSL Limited の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $15.74B | 2.04% |
| 2025 | $15.43B | 5.04% |
| 2024 | $14.69B | 11.51% |
| 2023 | $13.17B | 25.55% |
| 2022 | $10.49B | 1.56% |
| 2021 | $10.33B | 9.84% |
| 2020 | $9.41B | 13.08% |
| 2019 | $8.32B | 11.54% |
| 2018 | $7.46B | 6.28% |
| 2017 | $7.02B | 15.81% |
| 2016 | $6.06B | 11.00% |
| 2015 | $5.46B | 8.91% |
| 2014 | $5.01B | 10.79% |
| 2013 | $4.52B | -2.44% |
| 2012 | $4.64B | -3.37% |
| 2011 | $4.80B | 49.63% |
| 2010 | $3.21B | 6.25% |
| 2009 | $3.02B | -7.53% |
| 2008 | $3.26B | 42.87% |
| 2007 | $2.28B | 45.52% |
| 2006 | $1.57B | -1.58% |
| 2005 | $1.60B | 98.59% |
| 2004 | $803.28M | 36.45% |
| 2003 | $588.71M | 38.88% |
| 2002 | $423.90M | -2.21% |
| 2001 | $433.49M | 0.00% |
| 2000 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | -19.82% |
US
|
|
| $2.23B | -85.85% |
US
|
|
| - | - |
CH
|
|
| $6.02B | -61.76% |
NL
|
|
| $10.11B | -35.78% |
BE
|
